A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

Status Completed

Clinical Trial Summary

A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Healthy Females Aged 18-30 Years.

Clinical Trial Description

This is a multi-centre, randomized, double blinded, placebo controlled study. The study vaccine is recombinant human papillomavirus bivalent (types 16 and 18) vaccine (Yeast), the placebo is aluminium phosphate diluent. This study planned to enrol 12000 healthy female aged 18-30 in 10 study sites. Each participants will received a three-dose schedule of vaccine or placebo randomly but with the proportion controlled as 1:1 for vaccine group and placebo group. After each inoculation, the immediate reaction will be observed for 30 minutes, and the local and systemic reaction will be systematically observed for 7 days. After the first inoculation, adverse event will be collected until one month after the final inoculation, while serious adverse event will be collected until 6 months after the final inoculation. Blood samples will be collected before the first inoculation, and one month after the final injection, blood samples will also be collected in a group of participants containing 800 people to detect antibody titer. Follow-up visit will be conducted 14 times: month 0, month 0 + 8 days, month 2, month 2 + 8 days, month 6, month 6 + 8 days, month 7, month 12, month 18, month 24, month 30, month 36, month 48, month 60. When cervical intraepithelial neoplasia grade 2+ (CIN2+) is indicated, the participant will receive standard treatment and drop out from the study. ;

Study Design

Related Conditions & MeSH terms

Cervical Intraepithelial Neoplasia
Communicable Diseases
Human Papilloma Virus Infection Type 16
Human Papilloma Virus Infection Type 18
Infections
Papilloma
Papillomavirus Infections
Virus Diseases

Clinical Trial Details

NCT number	NCT02733068
Study type	Interventional
Source	Shanghai Zerun Biotechnology Co.,Ltd
Contact
Status	Completed
Phase	Phase 3
Start date	November 2, 2014
Completion date	January 16, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04537156` - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)	Phase 3
Completed	`NCT02907333` - Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia	N/A
Recruiting	`NCT02576262` - HPV Integration Testing for Human Papillomavirus-Positive Women	N/A
Completed	`NCT01029990` - Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program	Phase 0
Recruiting	`NCT05078528` - Low-cost Imaging Technology for Global Prevention of Cervical Cancer	N/A
Recruiting	`NCT05502367` - A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia	Phase 1/Phase 2
Completed	`NCT02494310` - HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings	N/A
Active, not recruiting	`NCT03429582` - Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device	N/A
Active, not recruiting	`NCT02140021` - Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer	N/A
Not yet recruiting	`NCT05510830` - Diagnostic Cervical Conization for Persistent Infection or Integration of HPV	N/A
Completed	`NCT02237326` - Visual Inspection With Acetic Acid Compared to Lugol's Iodine in HIV-infected Women	N/A
Completed	`NCT00316706` - Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine	Phase 3
Withdrawn	`NCT03143491` - Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)	Phase 2
Completed	`NCT03293628` - Comparing Two Techniques of Haemostasis After Cervical Conization	Phase 2
Recruiting	`NCT05266898` - Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV	Phase 4
Completed	`NCT02481414` - A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions	Phase 2
Completed	`NCT02247999` - Improving Cervical Cancer Screening Among HIV-Infected Women in India
Recruiting	`NCT04650711` - Immunohistochemical Staining of p16 for the Screening of Cervical Cancer	Phase 2
Recruiting	`NCT04646954` - DNA Methylation Testing for the Screening of Uterine Cervical Lesion	Phase 3
Completed	`NCT01544478` - V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.